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Although long recognized as a component of inflamed tissues, the potential role of cell death as an active 
component that contributes to tissue homeostasis, inflammation and disease pathogenesis has only recently 
gained attention (1). The notion that certain cell death regulatory components are hard-wired into 
inflammatory signalling pathways, such as those emanating from the TNF-receptor or Toll-related receptors, 
indicate that such death components act as positive regulators of tissue homeostasis, replacing 
malfunctioning or damaged tissues and enhancing the resilience of epithelia to tissue stress (1, 2).  
 
A number of dedicated sensors have evolved to detect different stressors and induce appropriate adaptive 
responses. Receptor-interacting serine/threonine-protein kinase 1 (Ripk1) represents such sensor, 
functioning as key signalling node in regulating adaptive responses to tissue stress (1). Ripk1 is activated in 
response to a variety of input signals, including those generated in response to TNF family cytokines, ligands 
for some Toll-like receptors (TLRs), pattern recognition receptors for viral infection, and interferons. Once 
activated, Ripk1 can signal for activation of MAP kinases, NF-B and apoptotic as well as necrotic cell death 
(necroptosis and pyroptosis) (1). Ripk1 mediates these effects in a kinase-dependent and/or scaffold-
dependent manner. While the scaffold function of Ripk1 is necessary to maintain tissue homeostasis (1), the 
kinase activity of Ripk1 is required for the induction of necroptosis, and, depending on the cellular context, 
apoptosis (3, 4). The kinase and scaffolding functions of Ripk1 are tightly controlled by ubiquitylation, 
phosphorylation, and caspase-mediated cleavage that regulate the integration of Ripk1 into distinct multi-
protein signalling complexes (1, 5, 6). Deregulation of Ripk1 has detrimental consequences as loss- or gain-
of-function of Ripk1 is associated with organismal lethality, aberrant cell death or chronic inflammation. 
Understanding how Ripk1 is regulated and how it initiates and escalates cell death and inflammation has 
important implications for normal development and disease pathologies, such as chronic inflammation and 
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cancer. But it also offers novel opportunities for immuno-oncology as Ripk1 and NF-kB signalling is required 
for antigen cross-priming of CD8+ T cells (7). 
 
In recent years, much has been learned about checkpoints of RIPK1 regulation, and the pathophysiological 
consequences of their deregulation. In the current issue of Nature, Peltzer and co-workers identified two new 
intricate pieces of the puzzle (2). They discovered that the LUBAC component Hoil-1 is essential to prevent 
aberrant Ripk1-dependent cell death. And more unexpectedly, they uncovered a novel cell death-
independent signalling output of Ripk1 that disrupts haematopoiesis in the developing embryo, and which is 
negatively regulated by LUBAC and Ripk3.  
 
LUBAC is a tripartite E3 ligase complex composed of Hoip, Hoil-1 and Sharpin, capable of synthesising 
linear ubiquitin chains on target substrates (2). The E3 ligase activity of LUBAC is required for optimal gene 
activation of pro-inflammatory genes downstream of innate immune receptors, such as TNFR1 and TLRs. 
Interfering with LUBAC activity not only delays the gene activation program but also unleashes the cytotoxic 
potential or Ripk1 kinase, which is thought to be one of the central LUBAC protein substrates. Genetic 
deletion of the LUBAC catalytic subunit Hoip was reported years back by Peltzer et al. to cause embryonic 
lethality at mid-gestation due to TNF-mediated cell death of endothelial cells, leading to vasculature defects 
(8). In the last issue of Nature, Peltzer et al. expand these studies and demonstrate that, similarly to Hoip, 
genetic deletion of Hoil-1 also causes embryonic lethality at mid-gestation due to death of endothelial cells of 
the yolk sac (9). Although this phenocopies loss of Hoip, the lethality of Hoil-1 deficient mice was 
unexpected, first because Hoil-1 E3 ligase activity is dispensable for LUBAC activity in vitro (10), and second 
because Tokunaga et al. previously showed that Hoil-1 deficient mice are viable (11). Peltzer et al. 
demonstrated that while loss of Hoil-1 catalytic domain has no impact on LUBAC activity, the absence of the 
UBL domain thwarts LUBAC assembly and its subsequent recruitment into the Tnfr1 signalling complex. 
Consequently, in the absence of LUBAC, TNF stimulates Ripk1-mediated cell death (9).  
 
The fact that Ripk1 kinase inactive mutant mice rescued the early lethality of Hoil-1 deficient mice is 
consistent with LUBAC being a negative regulator of RIPK1 kinase activity. However, this rescue was only 
partial, delaying death from mid- to late gestation. Hoil-1
-/- 
embryos still died due to persistent endothelial cell 
death at late gestation. To address whether Ripk1 kinase-independent cell death could contribute to the 
lethality of Hoil-1
-/-
 embryos at late gestation, the authors co-deleted Ripk3 and Caspase-8 in Hoil-1 null mice 
to abrogate both apoptosis and necroptosis. Surprisingly, co-deletion of Ripk3 and Caspase-8 did not confer 
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any survival advantage when compared to Ripk1 kinase inactivation, although cell death was blocked. Even 
more surprisingly, co-deletion of Caspase-8 and Mlkl allowed Hoil-1 null mice to be born and survive post the 
age of weaning. This unexpected difference between LUBAC/Ripk3 (lethal) and LUBAC/Mlkl (viable) double-
mutants prompted the authors to initially postulate that Mlkl might be activated independently of Ripk3 when 
LUBAC is missing. However, ablation of Mlkl in Hoil-1
-/-
Caspase-8
-/-
Ripk3
-/- 
mice failed to prevent embryonic 
lethality. Therefore, the absence of Ripk3, rather than the presence of Mlkl, was detrimental to LUBAC 
mutant embryos. This led the authors to conclude that Ripk3 must possess a previously unrecognised, pro-
survival function, which springs into action when both Hoil-1 and Caspase-8 are missing. Interestingly, Hoil-
1
-/-
Caspase-8
-/-
Ripk3
-/- 
embryos had severe early haematopoietic defects, indicating that Ripk3 ensures 
proper haematopoiesis in the absence of LUBAC and Caspase-8. To elucidate the target of Ripk3’s pro-
survival action, Peltzer and co-workers focused on Ripk1, since Ripk1 and Ripk3 bind to one another via 
their respective RHIMs (RIP homotypic interaction motif), and because Ripk1 is a key substrate of LUBAC. 
The quadruple Hoil-1
-/-
Caspase-8
-/-
Ripk3
-/-
Ripk1
-/-
 mouse finally solved the mystery. This quadruple KO 
mouse is indeed viable. This suggested that in the absence of Ripk3 and Hoil-1, Ripk1 exerts lethal functions 
during embryonic development by interfering with early haematopoiesis. Importantly, this lethal function 
seems to be independent of the kinase activity of Ripk1. 
 
Peltzer et al. therefore discovered a novel function for Ripk1. In the absence of Hoil-1 and Ripk3, Ripk1 acts 
as a negative regulator of haematopoiesis during embryonic development. The fact that neither Hoil-1 null 
mice nor Caspase-8
-/-
Ripk3
-/-
 exhibit defects in haematopoiesis suggests that Hoil-1 and Ripk3, individually, 
are sufficient to suppress this function of Ripk1. Mechanistically, it is not entirely clear how this works. While 
it is clear that the kinase activity of Ripk1 is not required for the new signalling role of Ripk1, it remains to be 
determined how Ripk1 impairs haematopoiesis via its scaffolding function. One possibility put forward by the 
authors is that deregulated Ripk1 drives ectopic cytokine production, which in turn interferes with 
haematopoiesis. In agreement with such a hypothesis, Hoil-1
-/-
Caspase-8
-/-
Ripk3
-/- 
animals harbour elevated 
levels of various cytokines. This is also consistent with a recent report from David Wallach’s group, indicating 
that Caspase-8
-/-
Ripk3
-/- 
embryos exhibit aberrant Ripk1-mediated cytokine production, albeit this does not 
result in pathological changes (12). According to this scenario, the high levels of cytokines of Caspase-8
-/-
Ripk3
-/-
 embryos would even further increase if Hoil-1 is co-deleted, removing the last inhibitory stop on 
Ripk1. This might ultimately lead to pathological levels of cytokines that could impair haematopoiesis. 
Clearly, further work is needed to test this hypothesis. Moreover, it remains enigmatic how LUBAC 
suppresses Ripk1 activity in the absence of Ripk3 and Caspase-8. While a direct regulation (LUBAC-
 4 
mediated ubiquitylation of Ripk1) is possible, given that LUBAC also controls optimal activation of IKK and 
NF-B-mediated gene expression, it is equally likely that LUBAC regulates Ripk1 activity indirectly, e.g. in a 
phospho- or transcription-dependent manner. Further, it remains unclear how Ripk1 is activated under these 
settings. Despite these open questions, the findings of Peltzer and colleagues clearly shed new light on the 
possible functions of Ripk1. 
 
Given that Ripk1 and NF-B signalling are required for antigen-cross priming of CD8+ T cells (7), a better 
understanding of Ripk1 regulation might also help to harness Ripk1 function for therapeutic purpose, 
particularly in the field of immunotherapy. Various cancer types loose expression of Ripk3 and/or acquire 
Caspase-8 inactivating mutations (13-15). Therefore, inactivating LUBAC might drive Ripk1-mediated 
cytokine production. Combining LUBAC inhibition with cell death inducing treatments might be a potentially 
effective approach to induce immunogenic cell death of malignant cells lacking Ripk3 and/or Caspase-8 
activity. This might in turn mobilise the immune system against malignant cells and lead to durable anti-
tumour immune responses. 
 
 
 
Figure 1 
Models depicting LUBAC- and Ripk-mediated regulation of embryonic development. The absence of LUBAC 
results in Ripk1/Ripk3/Caspase-8-dependent death of the embryo. Co-deletion of Caspase-8 and Mlkl 
restores embryonic development. However, when LUBAC, Caspase-8 and Ripk3 are mutated, Ripk1 drives 
ectopic activation of cytokine production, which might impede early haematopoiesis, leading to Ripk1-
mediated embryonic lethality. 
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